Last: | $13.27 |
---|---|
Change Percent: | -0.76% |
Open: | $13.29 |
Close: | $13.27 |
High: | $13.31 |
Low: | $13.21 |
Volume: | 1,033,508 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$13.27 | $13.29 | $13.27 | $13.31 | $13.21 | 1,033,508 | 05-02-2024 |
$13.19 | $13.1 | $13.19 | $13.2779 | $13.08 | 1,293,580 | 05-01-2024 |
$13.08 | $13.14 | $13.08 | $13.23 | $13.08 | 909,522 | 04-30-2024 |
$13.17 | $13.15 | $13.17 | $13.1885 | $13.11 | 1,333,089 | 04-29-2024 |
$13.03 | $13.08 | $13.03 | $13.08 | $13.005 | 1,213,476 | 04-26-2024 |
$13.07 | $13.15 | $13.07 | $13.19 | $13.05 | 1,697,077 | 04-25-2024 |
$13.23 | $13.32 | $13.23 | $13.33 | $13.21 | 924,523 | 04-24-2024 |
$13.38 | $13.37 | $13.38 | $13.41 | $13.3 | 1,702,435 | 04-23-2024 |
$13.36 | $13.31 | $13.36 | $13.41 | $13.295 | 1,561,448 | 04-22-2024 |
$13.24 | $13.18 | $13.24 | $13.26 | $13.17 | 1,316,677 | 04-19-2024 |
$13.16 | $13.16 | $13.16 | $13.225 | $13.12 | 1,287,745 | 04-18-2024 |
$13.15 | $13.18 | $13.15 | $13.18 | $13.11 | 1,639,877 | 04-17-2024 |
$13.23 | $13.22 | $13.23 | $13.3 | $13.22 | 2,279,140 | 04-16-2024 |
$13.18 | $13.31 | $13.18 | $13.345 | $13.17 | 1,788,861 | 04-15-2024 |
$13.37 | $13.51 | $13.37 | $13.56 | $13.35 | 2,244,598 | 04-12-2024 |
$13.58 | $13.49 | $13.58 | $13.6 | $13.465 | 3,030,911 | 04-11-2024 |
$13.57 | $13.5 | $13.57 | $13.59 | $13.455 | 2,418,988 | 04-10-2024 |
$13.65 | $13.67 | $13.65 | $13.69 | $13.59 | 1,432,021 | 04-09-2024 |
$13.67 | $13.63 | $13.67 | $13.775 | $13.62 | 2,064,229 | 04-08-2024 |
$13.62 | $13.52 | $13.62 | $13.62 | $13.44 | 1,822,690 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...